Superoxide dismutase (SOD) expression in tumor tissues was investigated in 10 cases of medulloblastoma by immunohistochemistry, using a monoclonal antibody against human copper and zinc-superoxide dismutase. Abundant SOD was expressed in tumors from patients with poor outcomes and little SOD in patients with good outcomes. These results suggest that resistance to adjuvant therapy depends on the amount of SOD in tumor tissues. The effects of adjuvant therapies for medulloblastomas depend on the production of free oxygen radicals, so if tumor cells contain a free radical scavenger such as SOD, the effects of adjuvant therapy may be reduced. Measurement of SOD in tumor tissues may be useful as a prognostic indicator for medulloblastoma.

Download full-text PDF

Source
http://dx.doi.org/10.2176/nmc.36.220DOI Listing

Publication Analysis

Top Keywords

tumor tissues
12
monoclonal antibody
8
antibody human
8
human copper
8
copper zinc-superoxide
8
zinc-superoxide dismutase
8
adjuvant therapy
8
sod tumor
8
effects adjuvant
8
sod
6

Similar Publications

Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).

View Article and Find Full Text PDF

Nanosize Non-Viral Gene Therapy Reverses Senescence Reprograming Driven by PBRM1 Deficiency to Suppress iCCA Progression.

Adv Sci (Weinh)

January 2025

Department of Hepatic Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

Polybromo-1 (PBRM1) serves as a crucial regulator of gene transcription in various tumors, including intrahepatic cholangiocarcinoma (iCCA). However, the exact role of PBRM1 in iCCA and the mechanism by which it regulates downstream target genes remain unclear. This research has revealed that PBRM1 is significantly downregulated in iCCA tissues, and this reduced expression is linked to aggressive clinicopathological features and a poor prognosis.

View Article and Find Full Text PDF

Objective: This study aimed to introduce and evaluate a novel software-based system, BioTrace, designed for real-time monitoring of thermal ablation tissue damage during image-guided radiofrequency ablation for hepatocellular carcinoma (HCC).

Methods: BioTrace utilizes a proprietary algorithm to analyze the temporo-spatial behavior of thermal gas bubble activity during ablation, as seen in conventional B-mode ultrasound imaging. Its predictive accuracy was assessed by comparing the ablation zones it predicted with those annotated by radiologists using contrast-enhanced computed tomography (CECT) 24 hours post-treatment, considered the gold standard.

View Article and Find Full Text PDF

Primary hepatocellular carcinoma (PHC) is the sixth most common cancer and the third leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for 75%-85% of PHC. LARP3 is aberrantly expressed in multiple cancers.

View Article and Find Full Text PDF

Nanocarriers have shown significant promise in the diagnosis and treatment of various diseases, utilizing a wide range of biocompatible materials such as metals, inorganic substances, and organic components. Despite diverse design strategies, key physicochemical properties, including hydrodynamic diameter, shape, surface charge, and hydrophilicity/lipophilicity, are crucial for optimizing biodistribution, pharmacokinetics, and therapeutic efficacy. However, these properties are often influenced by drug payload, presenting an ongoing challenge in developing versatile platform technologies for theranostics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!